Professor & Assoc. Dean of Research
Department of Pharmaceutical Sciences
Cationic antibiotic peptides, inflammation, innate immunity, inflammatory-mediated diseases, atherosclerosis, Alzheimer's disease, bacterial keratitis, sepsis, leukocyte biology, and leukocyte-endothelial interactions.
This laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.
Education & Experience
- Postdoctoral fellow/Immunology, Royal Children's Hospital, Melbourne, Australia, 1982-1984.
- Ph.D., Pathology, University of Melbourne, Australia. 1982.
- B.Sc. (Hon), Pathology. University of Melbourne, Australia,1976.
- B.Sc., Microbiology/Pathology. University of Melbourne, Australia, 1975.
- Dean, Graduate College, OUHSC, Oklahoma City, OK, 2014-present.
- Associate Dean for Research, College of Pharmacy, OUHSC, Oklahoma City, OK, 2009-present.
- Professor, Dept. Pharmaceutical Sciences, College of Pharmacy, OUHSC, Oklahoma City, OK, 2009-present.
- Chief Scientific Officer, Biolytx Pharmaceutical Corp (commercial development of an antibiotic based on CAP37 peptides for the treatment of severe Gram negative infections), 2005-present.
- Professor, Dept. of Pathology, 2009.
- Assoc. Professor, Dept. of Pathology, 1997-2009.
- Adjunct Professor, Dept. of Cell Biology, OUHSC, OKC, OK, 2009-present
- Adjunct Assoc. Professor, Dept. of Cell Biology & Surgery, OUHSC, OKC, OK, 1997-2009
- Adjunct Professor, Dept. of Pathology, OUHSC, OKC, OK, 2009-present
- Assistant Professor, Dept. of Pathology, OUHSC, OKC, OK, 1992-1997
- Assistant Professor, Dept. of Microbiology & Immunology, Emory University, Atlanta, GA, 1991-1992
- Senior Research Associate, Dept. of Microbiology & Immunology, Emory University, Atlanta, GA, 1984-1990.
Honors & Service
Fellow of the American Association for the Advancement of Science (AAAS) - honored for distinguished contributions to understanding innate immunity and inflammation and the application of host antimicrobial proteins against infections, 2013-2014.
Academic Research Fellow of the American Association of Colleges of Pharmacy (AACP), 2013-2014.
Governor (Mary Fallin)-appointed Oklahoma Health Research Committee member, 2013-2018.
OUHSC Patent Award, May 2013.
Henry Zarrow Presidential Professorship for meeting the highest standards of excellence in scholarship and teaching, 2008.
Chair, minisymposium "Host pathogen interactions and toll-like receptors." Experimental Biology 2008, San Diego, CA.
Finalist, Grace & Franklin Bernsen Foundation; Most Promising New Business Award to Biolytx Pharmaceuticals Corp., 2007.
"On the brink" award winner; Journal Record Innovator of the Year award, 2006.
Co-chair, minisymposium "Innate and acquired immunity," Experimental Biology, 2006, San Francisco, CA.
Discussion Leader, "Vascular Wall," Experimental Biology 2003, San Diego, CA.
Chair, "Mediators of Inflammation"; Experimental Biology 2000, San Diego, CA.
Society for Leukocyte Biology (SLB/FASEB), Grants and Corporate Relations Committee, Chair, 2015-2018.
US Army Clinical and Rehabilitative Medicine Research Program (CRMRP), Hypothesis Development Awards and Translational Research Awards of the Vision Research Program - Study Section Chair, 2014.
American Association of Colleges of Pharmacy (AACP) College of Deans; Task Force on assisting schools of Pharmacy at emerging research institutions, 2013-2014.
Society for Leukocyte Biology (SLB/FASEB), Grants and Corporate Relations Committee, member, 2012-2015.
North American Vascular Biology Organization (NVABO), Vascular Biology Publications Alert, Contributing Editor, 2011-2014.
Society for Neuroscience, "Department Chair Training to Increase Women in Neuroscience" (IWiN), September 15-16, 2011.
US Army Medical Research and Materiel Command (USAMRMC), ad hoc reviewer, 2011.
NIH/NEI Anterior Eye Disease study section - ad hoc member, 2008, 2009, 2010.
NIH Brain Disorders and Clinical Neuroscience (ZRGSBDCN-F02) study section, Oct. 10, 2008.
American Society for Investigative Pathology (ASIP) Program Committee member for Experimental Biology (EB 2007 & EB 2008).
NIH, Brain Disorders and Clinical Neuroscience BDCN-3 Study Section - ad hoc reviewer, 2001, 2002
American Heart Association, National Immunology & Microbiology I Study Section, 1999-2002
- "Biomarker and method for detecting a chronic inflammatory-associated disease." Patent No. 8,450,071 issued May 28, 2013.
- "Treatment of ocular wounds and ulcers." Patent No. 7,893,027 issued Feb. 22, 2011.
- "Method of predicting sepsis or an acute infectious inflammatory response." Patent No. 7,655,480 issued February 2, 2010.
- "Antifungal peptides and methods of use thereof. Patent No. 7,745,405, issued June 29, 2010.
- "Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides." Patent No. 7,354,900 issued April 8, 2008.
- "Antimicrobial peptides and methods of use thereof." Patent No. 6,730,659 issued May 3, 2004.
- "Antimicrobial peptides and methods of use thereof." Patent No. 6,514,701 issued February 4, 2003.
- "Antimicrobial peptides and methods of use thereof." Patent No. 6,107,460 issued August 22, 2000.
- "Method for treatment of bacterial infections." Patent No. 6,071,879 issued June 6, 2000.
- "Method for inhibiting production of tumor necrosis factor." Patent No. 5,877,151 issued March 2, 1999.
- "Method and composition for the treatment of septic shock." Patent No. 5,650,392 issued July 22, 1997.
- "Method and composition for the treatment of septic shock." Patent No. 5,627,262 issued May 6, 1997.
- "Method and composition for the treatment of septic shock." Patent No. 5,607,916 issued March 4, 1997.
- "Chemotactic, antibiotic and lipopolysaccharide binding peptide fragments of CAP37." Patent No. 5,484,855 issued January 16, 1996.
- "Method of increasing monocyte chemotaxis with CAP37 and monocyte chemotactic portions thereof." Patent No. 5,458,874 issued October 17, 1995.
- "Antifungal peptides and methods of use thereof." Austrailian Patent No. 2006275417 issued July 26, 2012.
- "Antifungal peptides and methods of use thereof." Mexican Patent No. MX/a/2008/001651, issued April 5, 2011.
Selected Publications & Presentations
Kasus-Jacobi A, Griffith GL, Noor-Mohammadi S, Logan S, Hinsley H, Brevetti J, Mathias L, Pereira HA. A mutlifunctional peptide based on the neutrophil immune defense molecule, CAP37, has antibacterial and wound healing properties. J Leukoc Biol 2015; 97: epub ahead of print. DOI: 10.1189/jlb 3A0214-104RR.
Griffith GL, Kasus-Jacobi A, Lerner MR, Pereira HA. Corneal wound healing, a newly identified function of CAP 37, is mediated by protein kinase C delta. Invest Ophthalmol Vis Sci 2014; 55: 4886-4895.
Griffith GL, Russell RA, Kasus-Jacobi A, Thavathiru E, Gonzalez ML, Logan S, Pereira HA. CAP 37 activation of PKC promotes human corneal epithelial chell chemotaxis. Invest Ophthalmol Vis Sci 2013; 54: 6712-6723.
Pereira HA, Tsyshevskaya-Hoover I, Hinsley H, Logan S, Nguyen M, Nguyen T-T, Pohl J, Wozniak K, Fidel Jr PL. Candidacidal activity of synthetic peptides based on the antibiotic domain of the neutrophil-derived protein, CAP37. Medical Mycology 2010; 48: 263-272.
Gordon YJ, Romanowski GG, Shanks RMQ, Yates KT, Hinsley H, Pereira HA. CAP37-derived antimicrobial peptides has in vitro antiviral activity against adenovirus and herpes simplex virus type 1. Curr Eye Res 2009; 34:241-249.
Casanegra A, Stoner J A, TAfur A J, Pereira H A, Rathbun S W, Gardner A W. Differences in galectin-3, a biomarker of fibrosis, between participants with peripheral arterial disease and participants with normal ankle-brachial index. Vascular Medicine. In Press;
MAkoni M, Eckert J, Pereira H A, Nizet V, Lawrence S M. Alterations in neonatal function attributable to increased immature forms. Early Human Development. In Press;
Silasi-Mansat R, Zhu H, Georgescu C, Popescu N, Keshari R S, Peer G, Lupu C, Taylor F B, Pereira H A, Kinasewitz G, Lambros J D, Lupu F. Complement inhibition decreases early fibrogenic events in the lung of septic baboons.. Journal of cellular and molecular medicine. 2015; 19: 2549-63.
Brock A J, Kasus-Jacobi A, Lerner M, Logan S, Adesina A M, Pereira H A. The antimicrobial protein, CAP37, is upregulated in pyramidal neurons during Alzheimer's disease. 2015; 144: 293-308.
Lawrence S M, Eckert J, Makoni M, Pereira H A. Is the Use of Complete Blood Counts with Manual Differentials an Antiquated Method of Determining Neutrophil Composition in Newborns?. Annals of clinical and laboratory science. 2015; 45: 403-13.
Current Grants Awarded
Current Grants Awarded
Role of CAP37 in neuroinflammation: Friend or foe? The major goal of this project is to investigate the CAP37/RAGE asix. HR12-068. Oklahoma Center for the Advancement of Science and Technology (OCAST), 07/01/12-06/30/15.
Oklahoma Shared Clinical and Translational Resources. The goal of the Key Component Activity that Dr. Pereira directs is to implement a seed/pilot grant program to help foster clinical and translational research throughout Oklahoma, as well as other IDeA states. NIH 1U54RR033563-01 IDeA Clinical Translational Resource Application. James (PI), 09/01/13-08/31/18.
Molecular Basis of Immunity. This is a training grant for graduate students and postdoctoral fellows in immunology. NIH/NIAID T32 - A107633-12. Cunningham (PI), 09/01/12-08/31/17.
Completed Research Support (past three years)
Development of an antimicrobial peptide therapeutic for Pseudomonas infections. The major goals of this project are to perform the critical pre-clinical experiments required to advance a novel antibiotic peptide for the treatment of hospital acquired infections into clinical trials. NIH/NIAID 1U01 A1075391, 09/01/07-08/31/12.
CAP37 and ocular inflammation. The major goals of this project are to determine the biological significance of the innate immune system molecular, CAP37, in corneal inflammation and to investigate its therapeutic potential for treatment of corneal wounds and infections. NIH/NEI 1R01 EY 015534-01A2, 09/30/07-08/31/12.